Phenotyping and Genotyping of Duffy Antigen

Plasmodium Vivax Clinical Trial

— DARC  

Official title:

Phenotyping and Genotyping of Duffy Antigen

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05527119
• Other study ID #: 8543
• Status: Completed
• Start date: March 11, 2022
• Est. completion date: September 11, 2023

Study information

• Verified date: November 2023
• Source: University Hospital, Strasbourg, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Malaria remains the world's leading parasitic endemic. Almost half of the world's population lives in endemic areas. Many at-risk people in African countries remain without access to malaria control. Malaria kills approximately 400,000 people each year, most of whom are children under the age of 5 in Africa. Since 2005, an increasing number of Plasmodium vivax infections have been observed in Duffy-negative populations in South America and Africa, calling into question the essential role of the PvDBP-DARC interaction. The objective of the investigators is therefore to study and understand the invasion pathways used by Plasmodium vivax in Duffy-negative subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: September 11, 2023
• Est. primary completion date: July 11, 2023
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Major subjects

• with malaria and willing to have their blood samples analyzed for this research

Exclusion Criteria:

• Subjects refusing to participate in the study

Related Conditions & MeSH terms

• Malaria
• Plasmodium Vivax

Locations

Country	Name	City	State
France	Service de Laboratoire de Parasitologie et Mycologie Médicale-PTM - CHU de Strasbourg - France	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of blood samples tested (phenotype and genotype).		2 months later